This is a $12,202,250.58 Cost Plus Fixed Fee definitive contract awarded by the Defense Threat Reduction Agency (DTRA) to Synergene Therapeutics Inc., a small business, on July 7, 2020. The contract is for the application of a nanocomplex technology to actively permeate the blood-brain barrier (BBB) under the STTR Phase III research program. The work will be performed in Potomac, Maryland and has an ultimate completion date of July 6, 2025. This contract award is set aside for small businesses.
Generated 10/2/24, 10:21 AM